Ferroptosis in haematological malignancies and associated therapeutic nanotechnologies
RL Mynott, A Habib, OG Best… - International journal of …, 2023 - mdpi.com
Haematological malignancies are heterogeneous groups of cancers of the bone marrow,
blood or lymph nodes, and while therapeutic advances have greatly improved the lifespan …
blood or lymph nodes, and while therapeutic advances have greatly improved the lifespan …
Research Progress on Ferroptosis in Multiple Myeloma
P Li, T Lyu - Current Treatment Options in Oncology, 2024 - Springer
Multiple myeloma (MM) is the second most common hematological malignant (HM) tumor,
and a large proportion of patients still suffer from treatment failure and a poor prognosis …
and a large proportion of patients still suffer from treatment failure and a poor prognosis …
[HTML][HTML] AP-1 inhibitor induces ferroptosis via the PI3K/AKT pathway in multiple myeloma cells
S Tang, J Liu, F Li, Y Yan, X Long, Y Fu - Heliyon, 2024 - cell.com
Multiple myeloma (MM) is an incurable malignancy of plasma cells that is sensitive to T-
5224, an AP-1 inhibitor. Previous study indicated that T-5224 inhibits proliferation and …
5224, an AP-1 inhibitor. Previous study indicated that T-5224 inhibits proliferation and …
Class II ferroptosis inducers are a novel therapeutic approach for t (4; 14)-positive multiple myeloma
J Zhang, Y Liu, L Zuo, F Fan, H Yan, F Zhao… - Blood …, 2024 - ashpublications.org
Multiple myeloma (MM) is a clonal plasma cell malignancy that is characterized by genetic
heterogeneity. The cytogenetic abnormality t (4; 14) strongly predicts poor outcome in …
heterogeneity. The cytogenetic abnormality t (4; 14) strongly predicts poor outcome in …
[HTML][HTML] Bone marrow stromal cells protect myeloma cells from ferroptosis through GPX4 deSUMOylation
H Jiang, Q Li, X Yang, L Jia, H Cheng, J Wang, S Wang… - Cancer Letters, 2025 - Elsevier
Bone marrow stromal cells (BMSCs) are vital for preventing chemotherapy induced
apoptosis of multiple myeloma (MM), but roles and machinery in other forms of cell death …
apoptosis of multiple myeloma (MM), but roles and machinery in other forms of cell death …
Changes in immune subsets during chemotherapy as prognosis biomarkers for multiple myeloma patients by longitudinal monitoring
P Xu, Y Li, X Zhuang, L Yue, Y Ma, W Xue, L Ji… - Immunologic …, 2024 - Springer
Multiple myeloma (MM) is a malignancy of plasma cells accompanied by immune
dysfunction. This study aimed to provide a comprehensive and dynamic characterization of …
dysfunction. This study aimed to provide a comprehensive and dynamic characterization of …
Identification of COQ2 as a regulator of proliferation and lipid peroxidation through genome‐scale CRISPR‐Cas9 screening in myeloma cells
M Li, C Zhang, D Zhou, SH Chan, XQ Liu… - British Journal of …, 2024 - Wiley Online Library
Multiple myeloma (MM) is the second most common malignant haematological disease with
a poor prognosis. The limit therapeutic progress has been made in MM patients with cancer …
a poor prognosis. The limit therapeutic progress has been made in MM patients with cancer …
Construction and experimental validation of a novel ferroptosis‐related gene signature for myelodysplastic syndromes
Y Zhu, J He, R Wei, J Liu - Immunity, Inflammation and Disease, 2024 - Wiley Online Library
Background Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders
characterized by morphological abnormalities and peripheral blood cytopenias, carrying a …
characterized by morphological abnormalities and peripheral blood cytopenias, carrying a …
DUBR/miR-17-3p/TFRC/HO-1 axis promotes the chemosensitivity of multiple myeloma
T Guo, F Zhang, H Wang, H Li, X Niu… - Critical Reviews™ in … - dl.begellhouse.com
Long non-coding RNAs (lncRNAs) are intensively involved in the pathogenesis of multiple
myeloma (MM). This study aimed to investigate the potentials of DUBR in MM. Gene …
myeloma (MM). This study aimed to investigate the potentials of DUBR in MM. Gene …